Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.

Bhogal, Talvinder; Khan, Umair T; Lee, Rebecca; Stockdale, Alexander; Hesford, Christian; Potti-Dhananjaya, Vaishnav; Jathanna, Avith; Rahman, Shaun; Tivey, Ann; Shotton, Rohan; Sundar, Ram; Valerio, Christopher; Norouzi, Amir; Walker, Philip; Suckling, Ruth; Armstrong, Anne; Brearton, Gillian; Pettitt, Andrew; Kalakonda, Nagesh; Palmer, Daniel H; Jackson, Richard; Turtle, Lance; Palmieri, Carlo

The COVID-19 pandemic has been a disruptive event for cancer patients, especially those with haematological malignancies (HM). They may experience a more severe clinical course due to impaired immune responses. This multi-center retrospective UK audit identified cancer patients who had SARS-CoV-2 infection between 1 March and 10 June 2020 and collected data pertaining to cancer history, COVID-19 presentation and outcomes. In total, 179 patients were identified with a median age of 72 (IQR 61, 81) and follow-up of 44 days (IQR 42, 45). Forty-one percent were female and the overall mortality was 37%. Twenty-nine percent had HM and of these, those treated with chemotherapy in the preceding 28 days to COVID-19 diagnosis had worse outcome compared with solid malignancy (SM): 62% versus 19% died [HR 8.33 (95% CI, 2.56-25), p < 0.001]. Definite or probable nosocomial SARS-CoV-2 transmission accounted for 16% of cases and was associated with increased risk of death (HR 2.47, 95% CI 1.43-4.29, p = 0.001). Patients with haematological malignancies and those who acquire nosocomial transmission are at increased risk of death. Therefore, there is an urgent need to reassess shielding advice, reinforce stringent infection control, and ensure regular patient and staff testing to prevent nosocomial transmission.